Cutera (NASDAQ:CUTR) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Cutera (NASDAQ:CUTR) in a report released on Monday. The brokerage set a “sell” rating on the medical device company’s stock.

A number of other equities research analysts also recently commented on CUTR. Piper Sandler reiterated a “neutral” rating and issued a $1.00 price objective (down previously from $3.00) on shares of Cutera in a report on Friday, August 9th. Stephens dropped their price target on shares of Cutera from $10.00 to $5.00 and set an “overweight” rating for the company in a research report on Friday, August 9th.

Cutera Price Performance

Shares of NASDAQ CUTR traded down $0.04 during trading hours on Monday, hitting $0.29. 584,775 shares of the stock were exchanged, compared to its average volume of 902,554. The firm has a market capitalization of $5.77 million, a P/E ratio of -0.04 and a beta of 1.35. Cutera has a one year low of $0.28 and a one year high of $4.97. The company’s 50 day moving average is $0.66 and its 200 day moving average is $1.23.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CUTR. Bayesian Capital Management LP purchased a new position in Cutera in the 1st quarter worth $33,000. Ground Swell Capital LLC purchased a new position in shares of Cutera during the second quarter valued at approximately $37,000. BNP Paribas Financial Markets grew its position in Cutera by 7.1% during the first quarter. BNP Paribas Financial Markets now owns 75,833 shares of the medical device company’s stock valued at $111,000 after buying an additional 5,017 shares during the period. Squarepoint Ops LLC boosted its position in shares of Cutera by 164.5% in the second quarter. Squarepoint Ops LLC now owns 113,964 shares of the medical device company’s stock worth $172,000 after purchasing an additional 70,870 shares during the period. Finally, Bank of Montreal Can increased its stake in shares of Cutera by 14.2% in the second quarter. Bank of Montreal Can now owns 282,704 shares of the medical device company’s stock worth $455,000 after purchasing an additional 35,248 shares in the last quarter. 90.70% of the stock is owned by institutional investors.

About Cutera

Cutera, Inc provides aesthetic and dermatology solutions for medical practitioners worldwide. It develops, manufactures, and markets energy-based product platforms for medical practitioners; and distributes third-party manufactured skincare products. The company provides AviClear for the treatment of mild, moderate, and severe inflammatory acne vulgaris; Secret PRO, a device that utilizes fractional CO2 for skin resurfacing and radio frequency (RF) microneedling for skin revitalization; truFlex, a bio-electrical muscle stimulation device designs to strengthen, firm and tone the abdomen, buttocks, and thighs; and excel V/V+, a vascular and benign pigmented lesion treatment platform.